[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lewy-body-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lewy-body-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,43,102,136,157,184,224,246,262,289,314,336,357,378,407,434,456,499,534,579],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100611455","digital-health-technologies-for-progressive-supranuclear-palsy-and-dementia-with-lewy-bodies-100611455",false,"NCT07240805","Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Digital Health Technologies For Monitoring Disease Symptoms in Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Inclusion Criteria:\n\n* Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.\n* Able to be present for all study procedures, complete questionnaires and assist during home data collection.\n* Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n* Ambulatory (able to take 10 steps with minimal support such as use of a cane)\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.","ALL","40 Years","89 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.",[25,26,27,28,29],"Progressive Supranuclear Palsy(PSP)","Dementia With Lewy Bodies (DLB)","PSP","Lewy Body Dementia (LBD)","Lewy Body Disease","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":21},"2026-06-15",{"date":38,"type":21},"2029-01-01",{"name":40,"class":41},"BioSensics","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":84,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","18 Years",{"count":53,"type":21},500,"INTERVENTIONAL",[56],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,29,82,83],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[85,86,63,64,87,88,77,89,68,82,80,90],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":94,"type":34},"2026-06-26",{"date":96,"type":34},"2016-06",{"date":98,"type":21},"2028-07-31",{"name":100,"class":41},"MD Stem Cells",3,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":54,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100642012","phase-2-a-study-of-donanemab-ly3002813-in-participants-with-early-cognitive-decline-trailblazer-alz-7-100642012","NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)","A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology","Inclusion Criteria:\n\n* Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months.\n* Have least 1 core clinical feature of dementia with Lewy bodies (DLB).\n* Have a score ≥20 on Montreal Cognitive Assessment (MoCA).\n* Meet plasma P-tau217 criteria.\n* Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology.\n* Have a CSF result consistent with the presence of alpha-synuclein pathology.\n* Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n\nExclusion Criteria:\n\n* Have a disease or condition that could interfere with this study or is a current serious or unstable illness.\n* Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study.\n* Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study.\n* Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions.\n* Have previously received amyloid-targeting therapy.\n* Active immunization against amyloid-beta.\n* Have a centrally read MRI that does not meet study entry criteria.\n* Have contraindication to MRI or PET scans.\n* Have any contraindication to lumbar puncture.","55 Years","85 Years",{"count":112,"type":21},350,[114],"PHASE2","The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.",[117,29,118,119],"Cognitive Dysfunction","Synucleinopathies","Amyloid",[121,122,123,60,61,124,125,79,117],"Mild Cognitive Impairment","Mild Dementia","Brain Diseases","Neurocognitive Disorders","Cognition Disorders","2026-06-16",{"date":128,"type":34},"2026-06-17",{"date":130,"type":34},"2026-05-20",{"date":132,"type":21},"2028-08",{"name":134,"class":41},"Eli Lilly and Company",72,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":156},"100642759","alpha-synuclein-education-and-disclosure-in-individuals-with-preclinical-and-symptomatic-lewy-body-disease-100642759","NCT07646652","Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease","Inclusion Criteria\n\nAll Participants\n\n* Able to provide 1) written, informed consent or 2) assent if a care partner can provide consent.\n* Access to a primary care or neurology provider for ongoing care.\n* 1\\) willing to undergo skin biopsy or lumbar puncture for alpha-synuclein testing or 2) has access to as-yet undisclosed skin biopsy or lumbar puncture alpha-synuclein testing results.\n\nHealthy\u002FAsymptomatic Arm\n\n* Undergoing testing for defined reason (e.g., research study)\n* Mini-Mental State Examination score between 26 and 30 (or MoCA between 25 and 30)\n* General good health (no diseases expected to interfere with the study)\n\nSymptomatic Arm \\[Concern for dementia with Lewy bodies (DLB), Parkinson's disease (PD), or multiple system atrophy (MSA)\\]\n\n* Referred by a neurologist or movement disorder specialist\n* Adults with any of the following: symptomatic LBD, mild cognitive impairment with Lewy body (MCI-LB), Parkinson's disease dementia (PDD), MCI in Parkinson's disease (PD-MCI), or criteria for multiple system atrophy (MSA).\n\nExclusion criteria:\n\nAll Participants\n\n* Clinician judgment that disclosure poses unacceptable psychological risk.\n* Concurrent enrollment in a trial with conflicting disclosure protocols.\n\nHealthy\u002FAsymptomatic Arm • Neurological diagnosis at the time of biomarker assessment (e.g., Alzheimer's disease, Parkinson's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, etc.)\n\nSymptomatic Arm\n\n• Absence of a caregiver who can complete assessments.",true,{"count":144,"type":21},40,"The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.",[29],"2026-06-08",{"date":36,"type":34},{"date":150,"type":21},"2026-11",{"date":152,"type":21},"2030-11",{"name":154,"class":155},"Stanford University","OTHER",1,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":142,"sex":16,"minAge":163,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":54,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":156},"100634883","retinal-hyperspectral-imaging-in-neurodegenerative-diseases-100634883","NCT07545473","Retinal Hyperspectral Imaging in Neurodegenerative Diseases","Inclusion Criteria:\n\n1. Aged over 30 years.\n2. Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited).\n3. With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests.\n4. Have a minimum best corrected visual acuity level of 6\u002F60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy.\n5. Be willing to participate in the study and attend the Centre for Eye Research Australia.\n6. Be accompanied by a friend or family member.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n3. Known contraindication to pharmacological pupil dilation\n4. Any condition that, in the investigator's opinion, would compromise participant safety or image quality","30 Years",{"count":165,"type":21},930,[56],"Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting \"hypercube\" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.",[80,61,79,169,81,170,29,171],"Parkinson Disease","Vascular Dementia","Niemann-Pick Diseases",[173,174],"Hyperspectral imaging","Retina","2026-04-21",{"date":177,"type":34},"2026-04-22",{"date":179,"type":34},"2021-10-11",{"date":181,"type":21},"2028-12-31",{"name":183,"class":155},"Center for Eye Research Australia",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":142,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":195,"conditions":196,"keywords":200,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":156},"100633985","the-swedish-biofinder-sleep-study-100633985","NCT07533799","The Swedish BioFINDER Sleep Study","BioFINDER-Sleep: Idiopathic REM-sleep Behavior Disorder & Early Parkinson's Disease","Inclusion Criteria:\n\nIdiopathic RBD:\n\n* Polysomnography verified RBD according to AASM criteria.\n* Does not fulfill diagnostic criteria for idiopathic Parkinson´s disease.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEarly Parkinson´s disease:\n\n* Fulfills the diagnostic criteria for idiopathic Parkinson´s disease.\n* The PD patients will be de novo (yet without any PD treatment) or with treatment for a maximum of 3 years.\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above. Healthy Controls\n* Age range 50-100. Women who are \\\u003C55 years of age will be required to take a pregnancy test before participation in the PET and scintigraphy part of the study if not post-menopausal.\n* No diagnosis of PD or another significant neurological disorder.\n* No diagnosis of RBD.\n* Ability to give informed consent.\n* Speaks Swedish fluently as stated above.\n\nExclusion Criteria:\n\nFor all groups:\n\n* Past history of severe or repeated concussive head injury or stroke or any significant systemic disease or unstable medical condition.\n* History of severe and unstable depression, schizophrenia, schizoaffective disorder or bipolar disorder.\n* Significant white matter microvascular disease.\n* Contraindication to MRI and PET.\n\nExclusion criteria specific for early Parkinson´s disease:\n\n* Normal dopamine transporter (\\[18F\\]FE-PE2I) scan.","50 Years","100 Years",{"count":194,"type":21},650,"BioFINDER-Sleep study was established in 2021 and will include patients with early Parkinson´s disease (PD) and persons with iRBD to provide essential insights into the underlying mechanisms of the progressive neurodegenerative processes in central and peripheral nervous systems. Briefly polysomnography will be used to establish the presence of RBD in both the early PD cohort and in the iRBD cohort. Then, state of the art multimodal imaging techniques will be used, including, magnetic resonance imaging (MRI), positron emission tomography (PET) of the dopamine transporters (DAT-PET) to quantify dopamine terminal loss, and \\[123I\\] MIBG scintigraphy of the heart will be performed to quantify the loss noradrenaline terminals to the heart. In addition to this, synuclein seed amplification assays (SSAs) will be applied to cerebrospinal fluid (CSF) and skin samples to establish synuclein pathology status. Further, CSF and blood biomarkers will be developed that can be used to as prognostic markers. These investigations will be done in parallel to clinical assessments of motor and non-motor symptoms as well as assessment of cognitive function in a longitudinal setting.",[197,198,29,199,118],"Parkinson´s Disease","REM Sleep Behavior Disorder (iRBD)","Synucleinopathy",[201,202,203,204,205,206,207,208,209,210,211,212,213,214],"Early diagnosis","CSF","Plasma","PET","MRI","DAT PET","Smell test","synuclein seed amplification assays","MIBG","Polysomnography","α-synuclein","Motoric test","cognitive test","UPDRS","2026-04-09",{"date":217,"type":34},"2026-04-16",{"date":219,"type":34},"2021-10-01",{"date":221,"type":21},"2033-06",{"name":223,"class":155},"Skane University Hospital",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":245,"locationsCount":156},"100525332","the-swedish-biofinder---primary-care-study-100525332","NCT06120361","The Swedish BioFINDER - Primary Care Study","ADetect","Inclusion Criteria:\n\n1. The patient seeks medical help because of cognitive symptoms experienced by the patient and\u002For informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.\n2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.\n3. Age ≥40 years\n4. Subjective cognitive decline, mild cognitive impairment or mild dementia\n\nExclusion Criteria:\n\n1. Already diagnosed dementia\n2. Significant unstable systemic illness or organ failure that makes it difficult to participate.\n3. Current significant alcohol or substance misuse.\n4. Refusing investigation at the Memory clinic\n5. Cognitive impairment with acute onset due to stroke\n6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.",{"count":232,"type":21},1200,"The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:\n\n1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care.\n2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care.\n3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care.\n4. Determine whether blood AD biomarkers improve patient management in primary care.",[122,121,235,79,29,236,170],"SCD","Frontotemporal Degeneration",[238],"Primary care, early diagnosis, blood, biomarkers, cognitive testing","2026-04-01",{"date":241,"type":34},"2026-04-06",{"date":243,"type":34},"2020-01-01",{"date":181,"type":21},{"name":223,"class":155},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":156},"100525490","the-swedish-biofinder---memory-clinic-study-100525490","NCT06122415","The Swedish BioFINDER - Memory Clinic Study","Validate","Inclusion Criteria:\n\n1. Under investigation for cognitive symptoms at the Memory clinic.\n2. Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.\n\nExclusion Criteria:\n\n1. Not undergoing CSF or blood sampling as part of clinical practice.\n2. Not undergoing cognitive testing as part of clinical practice.",{"count":232,"type":21},"The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests.\n\nIn this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps:\n\n1. Assessment without access to the results of either the blood test or cerebrospinal fluid test.\n2. Assessment with access to only the results of the blood test.\n3. Assessment with access to the results of both the blood test and cerebrospinal fluid test.\n\nAim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic.\n\nAim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.",[122,121,235,79,29,236,170],{"date":241,"type":34},{"date":258,"type":34},"2022-12-01",{"date":260,"type":21},"2026-12-31",{"name":223,"class":155},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":142,"sex":16,"minAge":269,"maxAge":192,"enrollmentInfo":270,"targetDuration":4,"studyType":54,"phases":272,"briefSummary":273,"conditions":274,"keywords":281,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":42},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.","20 Years",{"count":271,"type":21},2950,[56],"The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[80,79,169,29,275,236,276,277,74,278,279,121,280],"Parkinson-Dementia Syndrome","Semantic Dementia","Progressive Nonfluent Aphasia","Corticobasal Degeneration","Multiple System Atrophy","ALS (Amyotrophic Lateral Sclerosis)",[282],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test",{"date":241,"type":34},{"date":285,"type":34},"2017-05-15",{"date":287,"type":21},"2036-12",{"name":223,"class":155},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":54,"phases":297,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":156},"100416764","phase-3-18f-dopa-ii---pet-imaging-optimization-100416764","NCT04706910","18F-DOPA II - PET Imaging Optimization","Inclusion Criteria:\n\n1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.\n2. Pediatric patients (less than 18 years old) with neuroblastoma.\n3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.\n4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.\n5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.\n\nExclusion Criteria:\n\n1. Unable to obtain consent\n2. Weight \\>225 kg (weight limitation of PET\u002FCT scanner)\n3. Adult patients unable to lie flat for 20-30 minutes to complete the PET-CT session.\n4. Young pediatric patients (less than 13 years old) who are unable to lie flat for 20-30 minutes and for whom clinical sedation is contraindicated (as determined by a pediatric anaesthesiologist).\n5. Lack of intravenous access\n6. History of previous cholecystectomy (excluded from dynamic abdomen sub-study only)\n7. Pregnancy",{"count":296,"type":21},800,[298],"PHASE3","A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET\u002FCT imaging in specific patient populations:\n\n1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.\n2. Pediatric patients (less than 18 years old) with neuroblastoma.\n3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.\n4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.\n5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.\n\nImage optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.",[301,302,169,29,303,304],"Congenital Hyperinsulinism","Neuroblastoma","Neuroendocrine Tumors","Brain Tumor","2026-02-04",{"date":307,"type":34},"2026-02-09",{"date":309,"type":34},"2021-01-20",{"date":311,"type":21},"2027-12",{"name":313,"class":155},"University of Alberta",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":142,"sex":16,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":54,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":334,"locationsCount":156},"100504413","language-and-lewy-body-diseases-sentence-comprehension-problems-and-modifying-noninvasive-brain-stimulation-treatment-100504413","NCT05847985","Language and Lewy Body Diseases: Sentence Comprehension Problems and Modifying Noninvasive Brain Stimulation Treatment","LANG-LBD","Inclusion Criteria:\n\n* right-handedness\n* Czech as their first language\n* age (60-80 years)\n* presence of PD-MCI (Litvan et al. 2012) or MCI-LB (McKeith et al. 2020) for LBD subjects\n\nExclusion Criteria:\n\n* cardio pacemaker\n* any MRI-incompatible metal in the body\n* epilepsy\n* any diagnosed psychiatric disorders\n* alcohol\u002Fdrug abuse\n* for HC group the presence of LBDs or other neurodegenerative disorder or MCI\u002Fdementia","60 Years","80 Years",{"count":324,"type":21},90,[56],"Lewy body diseases (LBDs) represents a group of neurodegenerative disorders characterized by the abnormal accumulation of aggregates of α-synuclein protein leading to the formation of Lewy bodies (LB) and Lewy neurites resulting in cell death. LBDs consists of two major clinical entities - Parkinson's disease (PD) and dementia with LB (DLB). Vast majority of patients with LBDs either already have mild cognitive impairment (MCI) at the time of the diagnosis or will develop it during the course of the disease. Language dysfunctions in LBDs patients with MCI are often unrecognized, which are difficult to treat, but even subtle changes might lead to impairment of social and occupational functioning with profound effect on their quality of lives. Current pharmacological or surgical strategies are effective for tackling the motor issues of LBDs with very limited effects on other symptoms such as language dysfunctions. Therefore, non-pharmacological approaches are gaining more attention. One of these non-pharmacological strategies is the use of noninvasive brain stimulation (NIBS) techniques that are able to modulate the brain functions with the effects on human nervous system plasticity. In this proposed project the investigators aim to first describe specific alterations in the language domain in LBDs patients with MCI as compared to healthy controls (HC) and identify the neural underpinnings of these changes using novel combination of advanced multimodal imaging techniques and various analytical methods. Secondly, the investigators aim to use NIBS as a supervised and individualized home-based therapeutical approach to tackle the language dysfunctions.",[29,328],"Healthy Aging","2026-02-02",{"date":305,"type":34},{"date":332,"type":34},"2023-05-01",{"date":260,"type":21},{"name":335,"class":155},"Masaryk University",{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":142,"sex":16,"minAge":191,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":345,"conditions":346,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":156},"100520541","a-study-of-neurodegeneration-and-neuronal-fluctuations-in-lewy-body-disease-and-alzheimers-disease-100520541","NCT06057909","A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease","Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer Disease","Inclusion Criteria:\n\n* Use English as their primary language.\n* Be willing to undergo health and cognitive assessments, as well as brain MRI and EEG study.\n* Will be encouraged to have an available study partner (also called a \"co-participant\") who is familiar with the participant's daily functioning.\n* This study will be limited to healthy individuals, and patients who have a clinical diagnosis made by a board-certified neurologist of Lewy body disease or Alzheimer disease.\n* All individuals must be capable of providing informed consent and complying with the trial procedures. Realizing the challenge of obtaining informed consent from cognitively impaired individuals, time is specifically scheduled to foster an informative, supportive interview with the participant and caregiver\u002Flegal guardian (typically a spouse or child according to Arizona law and IRB guidelines).\n* Ongoing participation will be maintained by strict adherence to inclusion\u002Fexclusion criteria, clinical appropriateness (as determined by participant's physician and proxy\u002Ffamily), as well as by expressed wishes of family members\u002Fcaregivers\u002Fproxy discussed at each study visit (as appropriate).\n* All participants will receive copies of the signed ICFs (including signatures of those obtaining consent).\n* All participants have the right to withdraw from the study at any time.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they have significant sensory (visual and hearing) deficits or major medical or psychiatric illnesses which would limit participation.\n* Participants will also be excluded if they have history of other major neurologic disorders including stroke, epilepsy, meningitis\u002Fencephalitis, metabolic or toxic encephalopathy, penetrating or severe closed head injury, brain tumor\u002Fother structural lesion, other primary movement disorders (such as essential tremor, dystonia, chorea, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).\n* In addition, as necessitated by the risks of Magnetic Resonance Imaging (MRI), patients who have any type of implanted electrical device (such as a cardiac pacemaker or a neurostimulator including deep brain stimulation), or a certain type of metallic clip in their body (i.e., an aneurysm clip in the brain), are not eligible for participation in the MRI portion of the study. Individuals who experience claustrophobic anxiety will also be excluded from participation.\n* Women who are or might be pregnant and nursing mothers are not eligible.\n* If the subject is a woman of childbearing potential, due to unknown risks to the fetus, they must have a pregnancy test. Individuals who have a history metalworking involving cutting processes such as grinding, filing, shaving, and threading, or history of eye injury involving metal, will also be excluded unless they have had prior documented radiological clearance for MRI.","95 Years",{"count":324,"type":21},"The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and\u002For cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.",[29,79,347],"Healthy","2026-01-30",{"date":350,"type":34},"2026-02-03",{"date":352,"type":34},"2024-04-05",{"date":354,"type":21},"2027-06",{"name":356,"class":155},"Mayo Clinic",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":156},"100618751","dynamical-electrophysiology-and-neuropathology-in-lewys-bodies-disease-100618751","NCT07335692","Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease","DYNAPATH-LB","Inclusion Criteria:\n\n* Adult subjects (≥18 years old).\n* Subject who participated in the Alpha-Lewy-MA cohort and underwent RT-QuIC analysis.\n* Subject who underwent a standard EEG examination at HUS between January 1, 2012, and January 1, 2020.\n\nExclusion Criteria:\n\n\\- Subject who expressed opposition to participating in the study.",{"count":144,"type":21},"Lewy body disease (LBD) is a neurodegenerative disorder that causes cognitive and behavioral problems. However, it is difficult to diagnose, and its pathophysiology is still not fully understood. The usual diagnostic criteria for LBD have excellent specificity but poor sensitivity. In particular, we lack paraclinical tests that can make a significant contribution. LBD patients may exhibit abnormalities in brain activity dynamics, which can be detected by EEG and may be linked to neuronal dysfunctions specific to the disease. The objective of this study is twofold: first, to assess the validity of this observation, that is, to confirm that the observed phenomenon is indeed linked to the pathophysiology of LBD, and second, to clarify the nature of these abnormalities by exploring the brain dynamics of LBD patients in greater detail.",[29],[29,368],"Neurodegenerative disorder","2026-01-02",{"date":371,"type":34},"2026-01-13",{"date":373,"type":34},"2025-06-02",{"date":375,"type":21},"2026-06-02",{"name":377,"class":155},"University Hospital, Strasbourg, France",{"id":379,"slug":380,"hasResults":11,"nctId":381,"briefTitle":382,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":11,"sex":16,"minAge":321,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":54,"phases":387,"briefSummary":388,"conditions":389,"keywords":394,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":156},"100576488","tdcs-effect-on-psychotic-symptoms-in-dementia-with-lewy-bodies-dlb-and-impacts-on-caregiver-burden-100576488","NCT06785948","tDCS Effect on Psychotic Symptoms in Dementia With Lewy Bodies (DLB), and Impacts on Caregiver Burden","MCL-tDCS","Inclusion Criteria:\n\n* Male or Female, aged over 60,\n* Diagnosed with a neurodegenerative pathology of the DLB type, at a moderate stage, according to the McKeith and al. (2017) criteria\n* No change in antiparkinsonian or psychotropic medications, or cholinesterase inhibitors, for a period of one month prior to inclusion,\n* Mini Mental State Examination (MMSE) \\> 15,\n* Composite score called \"psychotic factor\" (corresponding to the sum of the psychotic-type symptoms sub-scores from the NPI \\[12\\]) greater than 0,\n* Presence of a family caregiver,\n* Sufficient written and oral expression in French,\n* Written informed consent signed by the patient and his\u002Fher family caregiver\n\nExclusion Criteria:\n\n* History of alcoholism, drug addiction or neurological diseases such as brain trauma, epilepsy, encephalitis, intracranial normal-pressure hydrocephalus, etc. which may lead to cognitive impairment,\n* Concomitant major psychiatric illness,\n* Significant physical illness or comorbidities\n* History of moderate to severe visual impairment secondary to glaucoma, cataract or macular degeneration,\n* Patient under guardianship or curators",{"count":386,"type":21},30,[56],"The goal of this pilot prospective study is to evaluate the effect of tDCS on psychotic-like symptoms in patients with Lewy Body Dementia (LBD). The main questions it aims to answer are:\n\n* What is the effect of tDCS on neuropsychiatric symptoms, especially psychotic-like symptoms?\n* What is the impact of tDCS on caregiver burden?\n\nResearchers will compare active tDCS (2mA stimulation, anode on the left dorsolateral prefrontal cortex, cathode on the right fronto-orbital) to Sham tDCS (placebo stimulation, no intensity applied) to see if there is an effect on reducing psychotic-like symptoms and on caregiver burden.\n\nParticipants will:\n\n* Undergo a stimulation phase consisting of 10 tDCS sessions of 20 minutes each, spread over 2 consecutive weeks (5 days with stimulation, 2 days without stimulation, 5 days with stimulation).\n* perform assessments at T0 (inclusion), T1 (at the end of the stimulation phase), and T2 (follow-up at 8 weeks post stimulation).",[390,391,392,29,393],"Lewy Body Dementia","Lewy Body Dementia With Behavioral Disturbance","Burden, Caregiver","Dementia With Lewy Bodies",[395,396,397,398],"Transcranial Direct-Current Stimulation (t-DCS)","Brain stimulation","Psychotic symptoms","Caregiver burden","2025-09-30",{"date":401,"type":34},"2025-10-01",{"date":403,"type":34},"2025-01-10",{"date":150,"type":21},{"name":406,"class":155},"Association de Recherche Bibliographique pour les Neurosciences",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":142,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":54,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":156},"100392395","oct-angiography-and-adaptive-optics-in-patients-with-memory-impairment-100392395","NCT04389437","OCT-Angiography and Adaptive Optics in Patients With Memory Impairment","OCTAVO","Inclusion Criteria:\n\n* Patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis)\n* history of retinal pathology\n* ametropia greater in absolute value than 3 diopters on the sphere, or\u002Fand 1.5 diopters on the cylinder.\n* history of taking ethambutol for more than 2 months\n* history of takingsynthetic antimalarial for more than 2 years\n* Mini Mental State Score (MMS) and \u002F or Montreal Cognitive Assessment (MoCA) \\\u003C10 for patients and 26 for accompanying persons\n* MRI contraindication (for patients only)",{"count":415,"type":21},450,[56],"Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or Lewy body diseases.\n\nThese retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD.\n\nNo study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.",[419,79,29,420],"Amnesia","Parkinsons Disease With Dementia",[422,423],"OCT-A","adaptative optics","2025-09-26",{"date":426,"type":34},"2025-09-29",{"date":428,"type":34},"2020-06-26",{"date":430,"type":21},"2026-06",{"name":432,"class":433},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":142,"sex":16,"minAge":51,"maxAge":192,"enrollmentInfo":441,"targetDuration":4,"studyType":54,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":156},"100440413","telehealth-in-lewy-body-dementia-100440413","NCT05014971","Telehealth in Lewy Body Dementia","Multi-Stakeholder Engagement for Interdisciplinary Telehealth in Lewy Body Dementia","Participant with Lewy Body Dementia (LBD) Inclusion Criteria:\n\n* LBD diagnosis by a dementia or movement disorders specialist\n* Clinician-determined mild-moderate dementia severity\n* Internet access with a Zoom-compatible device\n* Caregiver who resides in the patient's home and is willing to participate\n* Fluency in English",{"count":442,"type":21},106,[56],"Lewy body dementia (LBD) is the 2nd most common neurodegenerative dementia in the US. Optimal care requires an interdisciplinary approach, however often faced barriers include rural residence, limited access to specialists, travel distance, limited awareness of resources, and physical, cognitive, and behavioral impairments making travel to appointments challenging. Delivering interdisciplinary care remotely using video technology has the potential to improve access to care for patients with LBD.",[391,446,29],"Lewy Body Parkinson Disease","2025-06-25",{"date":449,"type":34},"2025-06-26",{"date":451,"type":34},"2022-02-28",{"date":453,"type":21},"2026-05-31",{"name":455,"class":155},"University of Florida",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":462,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":465,"conditions":466,"keywords":485,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":156},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":464,"type":21},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[75,76,79,467,468,469,278,80,81,470,29,87,279,169,471,74,472,473,474,475,476,477,478,479,480,481,482,483,484],"Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Huntington Disease","Parkinson's Disease and Parkinsonism","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[75,76,79,469,278,80,81,470,29,87,279,169,486,74,472,473,487,488,477,489,478,479,480,481,482,483,484],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":492,"type":34},"2025-03-03",{"date":494,"type":34},"2022-11-10",{"date":496,"type":21},"2045-11-10",{"name":498,"class":155},"New York Stem Cell Foundation Research Institute",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":142,"sex":16,"minAge":191,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":54,"phases":506,"briefSummary":507,"conditions":508,"keywords":514,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":156},"100572472","association-of-transcranial-alternating-current-stimulation-with-digital-cognitive-training-for-cognitive-remediation-in-older-adults-100572472","NCT06733714","Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults","Inclusion Criteria:\n\n* Healthy subjects over 50 years old, with cognitive complaints\n\nExclusion Criteria:\n\n* Estimated Intelligence Quotient \\\u003C80\n* Dependence on psychoactive substances (DSM-V)\n* Severe psychiatric or neurological disorders\n* Uncorrected visual\u002Fhearing problems\n* History of syncope for an unexplained reason or seizure less than a year ago\n* Previous stroke\n* Use of anticoagulants\n* Intracranial metallic prosthesis or cardiac pacemaker\n* Any contraindication to performing tACS",{"count":144,"type":21},[56],"BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.\n\nDigital Cognitive Training (DCT) and Transcranial Alternating Current Stimulation (tACS) are two promising tools for cognitive remediation in this population. In this exploratory study, we investigate feasibility, tolerability and preliminary effects of the association of both interventions in older adults with cognitive complaints.\n\nMETHODS Older adults with cognitive complaints are being enrolled for this study, which comprises 5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving theta tACS (6Hz, 1.6mA) targeting the Left Dorsolateral Prefrontal Cortex.",[117,79,121,509,236,80,510,29,511,512,513],"Cognitive Decline","Dementia, Vascular","Beta-Amyloid","GFAP","Tau Protein",[515,516,517,518,519,520,521,522,523,524],"tacs","nibs","transcranial alternate current stimulation","mild cognitive impairment","MCI","ALzheimer","Cognition","Elderly","Older Adults","Cognitive enhancement","2024-12-09",{"date":527,"type":34},"2024-12-13",{"date":529,"type":34},"2024-12-02",{"date":531,"type":21},"2027-03-01",{"name":533,"class":155},"Universidade Federal do Rio de Janeiro",{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":16,"minAge":542,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":545,"conditions":546,"keywords":555,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":577,"locationsCount":156},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":544,"type":21},600,"MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[61,169,118,29,279,547,79,278,548,549,550,76,551,552,82,80,553,554],"Tauopathies","Supranuclear Palsy, Progressive","Atypical Parkinsonism","TDP-43 Proteinopathies","Frontotemporal Lobar Degeneration","Movement Disorders","Iron Overload","Neurodegeneration With Brain Iron Accumulation (NBIA)",[61,556,557,558,559,560,561,562,563,564,565,566,567,568,569],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":572,"type":34},"2024-09-19",{"date":574,"type":21},"2024-09-09",{"date":576,"type":21},"2034-09-09",{"name":578,"class":433},"Casa di Cura San Raffaele Cassino",{"id":580,"slug":581,"hasResults":11,"nctId":582,"briefTitle":583,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":54,"phases":587,"briefSummary":589,"conditions":590,"keywords":591,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":156},"100393634","phase-1-ambroxol-as-a-novel-disease-modifying-treatment-for-lewy-body-dementia-100393634","NCT04405596","Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia","Inclusion Criteria:\n\n1. Probable diagnosis of Lewy Body Dementia\n2. Age greater than 50 years old\n3. Montreal Cognitive Assessment (MoCA) score: 24-18\n4. Patients must have a responsible caregiver = 4days\u002Fweek\n5. Must be on a stable dose of medications for parkinsonism (levodopa, dopaminergic agonist) and cognition (cholinesterase inhibitors) and psychiatric (i.e. antidepressants, antipsychotic) for at least 3 months prior to the study\n\nExclusion Criteria:\n\n1. Evidence of stroke or other neurological condition\n2. Any other serious underlying condition or brain disorder that can account in part of in full for the clinical presentation (i.e. cancer or unstable cardiac disease etc.)\n3. Contraindication to MRI e.g. presence of metal fragments in head or eye, implanted electrical devices or conductive implants or devices (pacemakers, neurostimulators).\n4. Unable to undergo DAT-scan\n5. Depression that is, in the opinion of the investigator, significant enough to interfere with neuropsychology and safety assessments\n6. Females who are pregnant or breastfeeding, or planning to conceive within the study period\n7. Concurrent treatment with oral anticoagulants (including Vitamin K agonists and Novel Oral Anticoagulants (NOACs)) within 4 weeks of screening or anticipated during the 52 week double-blind and open label periods. Specifically, Apixaban, Dabigatran, Edoxaban, Fondaparinux, Rivaroxaban, and Warfarin are prohibited concomitant medications. Exceptions: antiplatelet agents such as Aspirin, Clopidogrel, and Aggrenox.",{"count":586,"type":21},15,[588,114],"PHASE1","This is a randomized, placebo-controlled, double-blind study investigating whether the medication Ambroxol is safe,effectiveness and well tolerated for the treatment of Lewy Body Dementia (LBD). Currently the main treatments for patients with LBD target symptom management. However, none of the medications treat the underlying cause of the disease, which includes the accumulation of protein in the brain. Therefore, even if patients respond well to symptomatic treatment, they continue to deteriorate. Therefore, the purpose of the current study is to make sure Ambroxol is safe to take long term and to test the effects of Ambroxol in treating the cognitive impairments associated with LBD by modifying the underlying causes of the disease.\n\nThere will be a total of 15 people participating this this study, which will last 52 weeks. Over the study period patients will undergo clinical, neuropsychological and neuroimaging assessment to assess changes.",[29],[29,592,521,80],"Ambroxol","2023-12-12",{"date":595,"type":34},"2023-12-13",{"date":597,"type":21},"2025-01",{"date":599,"type":21},"2027-01",{"name":601,"class":155},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's"]